BRCA1 and neoplasm: PARP inhibitors are synthetically lethal in tumours with homologous recombination deficiencies (HRD), in particular in tumours with either a germline or somatic mutation in the breast cancer type 1/2 susceptibility gene (BRCA1/2) [5].